Opioid prescribing among new users for non-cancer pain in the USA, Canada, UK, and Taiwan: A population-based cohort study

Abstract

Background The opioid epidemic in North America has been driven by an increase in the use and potency of prescription opioids, with ensuing excessive opioid-related deaths. Internationally, there are lower rates of opioid-related mortality, possibly because of differences in prescribing and health system policies. Our aim was to compare opioid prescribing rates in patients without cancer, across 5 centers in 4 countries. In addition, we evaluated differences in the type, strength, and starting dose of medication and whether these characteristics changed over time. Methods and findings We conducted a retrospective multicenter cohort study of adults who are new users of opioids without prior cancer. Electronic health records and administrative health records from Boston (United States), Quebec and Alberta (Canada), United Kingdom, and Taiwan were used to identify patients between 2006 and 2015. Standard dosages in morphine milligram equivalents (MMEs) were calculated according to The Centers for Disease Control and Prevention. Age- and sex-standardized opioid prescribing rates were calculated for each jurisdiction. Of the 2,542,890 patients included, 44,690 were from Boston (US), 1,420,136 Alberta, 26,871 Quebec (Canada), 1,012,939 UK, and 38,254 Taiwan. The highest standardized opioid prescribing rates in 2014 were observed in Alberta at 66/1,000 persons compared to 52, 51, and 18/1,000 in the UK, US, and Quebec, respectively. The median MME/day (IQR) at initiation was highest in Boston at 38 (20 to 45); followed by Quebec, 27 (18 to 43); Alberta, 23 (9 to 38); UK, 12 (7 to 20); and Taiwan, 8 (4 to 11). Oxycodone was the first prescribed opioid in 65% of patients in the US cohort compared to 14% in Quebec, 4% in Alberta, 0.1% in the UK, and none in Taiwan. One of the limitations was that data were not available from all centers for the entirety of the 10-year period. Conclusions In this study, we observed substantial differences in opioid prescribing practices for non-cancer pain between jurisdictions. The preference to start patients on higher MME/day and more potent opioids in North America may be a contributing cause to the opioid epidemic. Using population-based cohorts in North America, UK and Taiwan, Dr. Meghna Jani and colleagues describe opioid prescribing rates in patients with non-cancer pain who are using opioids for the first time. Author summary Why was this study done? An opioid crisis has affected several high-income countries, especially in North America, followed by sharp increase in opioid-related deaths in recent years. There is little evidence on how opioid prescribing rates compare internationally and the differences between countries in the type, strength, starting dose of opioids, and whether these characteristics change over time. What did the researchers do and find? We analyzed data from 2,542,890 adults who were prescribed opioids for the first time between 2006 to 2016 in 4 countries and 5 jurisdictions (United States, Boston; Canada, Quebec and Alberta; United Kingdom; Taiwan). The highest opioid prescribing rates in 2014 were observed in Alberta at 66/1,000 persons compared to 52, 51, and 18/1,000 in the UK, US, and Quebec, respectively, after standardizing for age and sex. Median morphine milligram equivalents (MMEs)/day at first use was highest in Boston at 38 MME/day and in contrast were less than half of the US in the UK (12 MME/day) and Taiwan (8 MME/day). Oxycodone was the first prescribed opioid in 65% of patients of the US cohort compared to 14%, Quebec 4%, Alberta; 0.1%, UK; and none in Taiwan. At initiation of an opioid, 20% of US patients, 13% of Quebec patients, and 10% of Albertans exceeded the US CDC–recommended threshold of 50 MME/day compared to 0.6% in the UK and 0.2% in Taiwan. What do these findings mean? In one of the first international comparisons to our knowledge, the preference to initiate patients on higher MME/day and more potent opioids in North America may be a contributing factor to the opioid epidemic.